Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for chronic palmoplantar pustular psoriasis
2013-003086-34Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in Palmoplantar Pustular Psoriasis (PPPP) (3 arms), sponsored by Novartis. Primary endpoint: ppPASI 75 response rate. Started Nov 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on 2013-003086-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003086-34.